Pharmaceutical

FDA accepts Sentynl’s Menkes disease therapy NDA for priority review

The FDA has accepted for filing and priority review Sentynl Therapeutics’ CUTX-101 NDA for the treatment of Menkes disease.

Jan 8, 2025 - 06:00
FDA accepts Sentynl’s Menkes disease therapy NDA for priority review
The FDA has accepted for filing and priority review Sentynl Therapeutics’ CUTX-101 NDA for the treatment of Menkes disease.
Read the original article

Tags:

Previous Article

WuXi Biologics to sell Ireland-based vaccine site to MSD for $500m

Next Article

FDA grants ODD to Tempest’s hepatocellular carcinoma treatment

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: FTC widens probe into pharmacy benefit managers to include group purchasing organizations

STAT+: FTC widens probe into pharmacy benefit managers ...

May 17, 2023

STAT+: Hospitals say violence against health workers is surging. Tech companies are stepping in to help

STAT+: Hospitals say violence against health workers is...

Nov 15, 2023

NPX-267 by NextPoint Therapeutics for Endometrial Cancer: Likelihood of Approval

NPX-267 by NextPoint Therapeutics for Endometrial Cance...

Jun 14, 2024